Roche firm on Genentech offer

Deal-watchers, take comfort. Roche says it's standing by its $43.7 billion offer to buy the rest of Genentech it doesn't own. Yes, there's been little activity on that deal lately, but Roche says it's still hungry for the buyout--and because Genentech shares have dropped below the $89 offer price, it might just decide to deal. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.